

# Recurrent Miscarriage: definition issues

### M. Goddijn E. van den Boogaard

ESHRE Campus, Rotterdam dec 2009



### **Recurrent Miscarriage: definition issues**

- Background
  - Recurrent miscarriage work up
  - Guidelines
- Two versus three or more miscarriages
- Maternal Age
- Consecutive versus non-consecutive
- Conclusions



### **Definition Recurrent Miscarriage**

- Good Clinical Practice starts with a clear definition of the clinical problem
- Definitions vary
  - Country
  - Professional Association (ESHRE/RCOG/ACOG)
- No consensus with regard to
  - Number of preceding miscarriages
  - Gestational age of miscarriages
  - Consecutive vs non-consecutive miscarriages



### **Definition Recurrent Miscarriage**

ACOG2001:≥ 2 consecutive miscarriages < 15 weeks GA</th>RCOG2003:≥ 3 miscarriagesESHRE2006:≥ 3 consecutive miscarriages < 20 weeks GA</td>NVOG2007:≥ 2 miscarriages< 20 weeks GA</td>





**Royal College of Obstetricians and Gynaecologists** Setting standards to improve women's health







### **Recurrent miscarriage work-up**



All couples: advise healthy life style



### **Recurrent miscarriage work-up**

#### Advice<sup>1</sup>

favour evidence based managementpromote Randomised Controlled Trials

### **Practice**<sup>2</sup>



- too many diagnostic tests and ineffective interventions performed
- adherence to the guideline Recurrent Miscarriage rather poor



### **Definition evidence**

- Absence of evidence
  - Definition is not a topic of research
- Try to define RM using data instead of discussions
  - 2 vs 3
  - Role of maternal age
  - Consecutive versus non-consecutive
  - Gestational age of miscarriages



### **Definition evidence**

- Absence of evidence
  - Definition is not a topic of research
- Try to define RM using data instead of discussions
  - 2 vs 3
  - Role of maternal age
  - Consecutive versus non-consecutive
  - Gestational age of miscarriages



# Selective karyotyping

- Maternal age is a the strongest risk factor for a structural chromosome abnormality
- The higher maternal age the lower the chance of a structural chromosome abnormality
- Other factors contributing to the risk:
  - History of  $\geq$  3 miscarriages vs 2 miscarriages
  - History of  $\geq$  2 miscarriages in a brother or sister
  - History of  $\geq$  2 miscarriages in a parent

6 centres for clinical genetics279 carrier couples428 non-carrier couples





# Selective karyotyping

Maternal age (years)		RM parents +		RM parents -	
at second miscarriage		≥3 misc.	2 misc.	≥3 misc.	2 misc.
. 00	RMbs +	10.2%	7.3%	7.3%	5.2%
< 23	RMbs -	5.7%	4.0%	4.1%	2.8%
22.24	RMbs +	10.0%	7.2%	7.2%	5.1%
23-34	RMbs -	5.7%	4.0%	4.0%	2.8%
04.07	RMbs +	5.8%	4.1%	4.1%	2.9%
34-37	RMbs -	3.2%	2.2%	2.2%	1.6%
37-39	RMbs +	4.0%	2.8%	2.8%	2.0%
	RMbs -	2.2%	1.5%	1.5%	1.1%
≥ 39	RMbs +	1.8%	1.2%	1.3%	0.9%
	RMbs -	1.0%	0.7%	0.7%	0.5%

Adopted in guidelines: ESHRE 06, NVOG 07



### **Pregnancy outcome RM unexplained**

Success rate (≥ 24 weeks)

Number of miscarriages  $\rightarrow$ 

	N=222	2	3	4	5
Female age	25	89	86	82	79
$\downarrow$	30	84	80	76	71
	35	77	73	68	62
	40	69	64	58	52
	45	60	54	48	42

Overall 75% chance of a successful pregnancy

### **Pregnancy outcome RM unexplained**

- The higher maternal age, and the higher the number of preceding miscarriages, the lower the chance of success
- Maternal age is a stronger risk factor when compared to number of miscarriages
- Maternal age is not taken into account in any definition





# **Dutch Guideline (NVOG) 2007**

	Do	Don't	Evidence Level
PGS		Х	No RCTs
PGD (indication of structural chromosome abnormality in male or female partner)	?*		No RCTs
Progesterone or hCG		Х	В
Correction of uterine anomaly		Х	No RCTs
Anticoagulant treatment (indication antiphospholipid syndrome)	Х		В
Anticoagulant treatment (indication hereditary thrombophilia factor)		X	В
Advise to lose weight	Х		В
Stop smoking	X		В
Eat healthily	Х		С
Calculate prognosis for subsequent pregnancy (if unexplained recurrent miscarriage)	Х		В



NVOG guideline Recurrent Miscarriage 2007 translation: NGC website www.guideline.gov



## **ALERT** implementation study

- Retrospective cohort study
- 9 departments of Obstetrics and Gynaecology in The Netherlands
- Patients with recurrent miscarriage in 2006
- Hospital financial registries (≥1 miscarriage) and centers for Clinical Genetics
- Medical charts and patient questionnaires



## **ALERT** implementation study

- Measurement of actual care
- Identify barriers and facilitators
- Develop a strategy for improvement









# **Quality indicators**

- Quality indicator = measurable element of practice performance for which there is evidence or consensus that it can be used to assess the quality of care<sup>1</sup>
- Developed in a systematic consensus procedure, using written questionnaires<sup>2,3</sup>
- Clinical experts on RM care







K	EY RECOMMENDATIONS ELIGIBLE FOR INDICATOR TRANSCRIPTION	Level of evidence	e
1	Report the number of objectified miscarriages		D
Chr	omosome abnormalities		
2	Record maternal age at the time of the 2nd miscarriage		В
3	Ask for family history with regard to recurrent miscarriage in parents and brothers/sisters of both partners		В
4	Perform karyotyping selectively		В
5	Refer all couples which were found to be carrier of a balanced structural chromosome abnormality to a clinical ge	eneticist	D
	1. Report the number of objectified miscarria	ages	
8	Start anticoagulant treatment in patients diagnosed with anti-phospholipid syndrome, according to the modified	schedule of R	ai B
Tro	mbophilia		
9	Report on history of thrombo-embolisms in all women		В
10	Report on family history of Thrombophilia and thrombo-embolisms		В
11	Perform screening for thrombophilia only in high risk patients		В
Hor	nocystein	ae Vereniging voer	
12	Determine random homocystein in all patients	In Granecologue In Dirichard	В
13	Supplement vitamins of low vitamin levels are found in hyperhomocysteinemia		С
Life	style		
14	Ask for lifestyle, including smoking habits of both patient and partner		В
15	Quit smoking for both patient and partner (in case of smoking)		В
16	Determine length and weight and calculate Body Mass Index (BMI)		В
17	Advise to loose weight, (in case of overweight)		В
Gen	neral second		
18	Prescribe new treatments <i>only</i> in the setting of a Randomised Clinical Trial		D
19	Withhold immunotherapy		А
20	Withhold therapy with aspirin in unexplained RM		В
21	Advise preconceptional folic acid (0,4-0,5 mg) to all patients		A
22	Offer Tender Loving Care in unexplained RM van den Boogaard RBMonline	e in press	С
23	Determine and discuss individual chances for success in the next pregnancy		В

### Report the no. of objectified miscarriages



no of women with RM and documentation of no of obj misc

X 100 = ... %

all women with RM

## How to improve adherence?





### **Pocket card**

Richtlijn Herhaalde Miskraam					
Definitie:	≥ 2 miskramen (AD tot 20 wel	ken) in de voorge	eschiedenis.		
Anamnese:	Obstetrische anamnese Levensstijl Trombose / Trombofilie	sche anamnese Familie HM ouders (중약) stijl anamnese: HM broer/zus (중약) se / Trombofilie Trombose 1 <sup>ste</sup> graad Trombofilie 1 <sup>ste</sup> graad			
Diagnostiek: Standaard	Lengte + Gew + BMI AFS: LAC, ACA IgG-IgM Homocysteïne	.engte + Gew + BMI <b>Op indicatie</b> Karyotypering ♂♀ (z.o.z.) FS: LAC, ACA IgG-IgM Trombofiliescreening łomocysteïne			
Beleid: Standaard	eleid: andaard Gezonde leefstijl <mark>Op indicatie</mark> Afvallen (BMI >25) Counseling, TLC Stoppen met roken ♂♀				
Therapie:	AFS: preconceptioneel ascal, fraxiparine bij HA + Hyperhomocysteïnemie: z.n. FZ, Vit B12, Vit 16 suppleren Trombofiliefactor: overleg stollingsarts Afwijkend karyogram: i.c.c. klinisch geneticus			Ouideline Recurrent Miscarriage	
www.nvog-docu	www.nvog-documenten.nl/www.herhaaldemiskraam.nl ALERT				



### **Electronic Decision aid**

#### Advies programma bij herhaalde miskramen.

#### Uitleg Totaal aantal geobjectiveerde miskramen, dat wil zeggen met op zijn No of obj misc 5 🗸 minst een positieve zwangerschapstest: Leeftijd in jaren op het moment van de tweede miskraam: Maternal age at 2nd misc 31 🗸 Lengte in cm: 173 🗸 Length cm Gewicht in kg: 95 🗸 Weight kg ja / nee Rookt u: $\bigcirc / \odot$ Smoking (♀) Rookt uw partner: $\odot / \odot$ Passive smoking ( $\mathcal{Z}$ ) Herhaalde miskraam bij ouders van patiënte/partner : $\bigcirc / \odot$ Herhaalde miskraam bij broers/zussen van patiënte/partner : Family History RM $\odot$ / $\bigcirc$ Heeft u ooit trombose gehad $\odot$ / $\bigcirc$ -sibs Trombose 1ste graads familielid $\bigcirc / \odot$ Trombofilie bij hetzelfde familielid $\bigcirc / \odot$ -parents Go Thrombosis Family history thrombosis Family history Thrombophilia



### **Electronic Decision aid**

Autros programma bij normaaldo miokramon.				
Relevante vragen	Antwoord	Advies		
Rookt uw partner :	Ja	Stoppen met roken.	Stop smoking	
Lengte : Gewicht :	1.73 95	Afvallen	Loose weight	
BMI :	31.7		Risk of carrier status: 7.2%	
HM bij ouders van patiënte/partner : HM bij broer/zus van patiënte/partner : Aantal miskramen :	Nee Ja 5	Risico op gebalanceerde chromo Karyotypering patiënte en partno	=> parental karyotyping	
Heeft u ooit trombose gehad : Trombose 1ste graads famililid : Trombofilie bij hetzelfde familielid :	Ja Nee Nee	Trombofiliefactoren bepalen		
Standaard		Antipfospholipiden antistoffen be Homocysteïne bepalen Gezonde leefstijl Foliumzuur	epalen	

Advies programma bij herhaalde miskramen.

Naar uitslagen en beleid



### **Definition evidence**

- Absence of evidence
  - Definition is not a topic of research
- Try to define RM using data instead of discussions
  - 2 vs 3
  - Role of maternal age
  - Consecutive versus non-consecutive
  - Gestational age of miscarriages



### **Does sequence matter?**





- Case-control study (1:2)
- Six centres for Clinical Genetics, The Netherlands<sup>1,2</sup>
- Period: 1992-2003
- Definition of consecutive: two preceding miscarriages in a row not interspersed with another pregnancy
- 707 couples
  - 279 carrier couples
  - 428 non-carrier couples



Examples of consecutive vs non-consecutive miscarriages



M= miscarriage, LB=livebirth



Baseline characteristics for patients with ≥2 miscarriages

≥ 2 miscarriages (n=707)	Carriers n=279	Non-carriers n=428	P- value
Maternal age in years at time of chromosome analysis	31.8 (4.3)	32.7 (5.0)	0.012
Maternal age in years at second miscarriage	30.5 (4.2)	31.6 (4.9)	0.002
Number of preceding miscarriages before chromosome analysis	3.0 (1.2)	2.8 (1.1)	0.004
Number of preceding live births - median (min-max)	0.0 (0-6)	1.0 (0-5)	0.029
Consecutive miscarriages - number (%)	256 (92%)	381 (89%)	0.21



Baseline characteristics for patients with ≥3 miscarriages

≥ 3 miscarriages (n=386)	Carriers n=170	Non-carriers n=216	P- value
Maternal age in years at time of chromosome analysis	31.7 (4.3)	32.6 (5.3)	0.07
Maternal age in years at second miscarriage	29.9 (4.2)	30.8 (5.1)	0.06
Number of preceding miscarriages before chromosome analysis	3.7 (1.2)	3.5 (1.0)	0.20
Number of preceding live births - median (min-max)	1.0 (0-6)	1.0 (0-5)	0.14
Consecutive miscarriages - number (%)	132 (78%)	168 (78%)	0.98



Probability of carrying a structural chromosome abnormality

	Univariable regression analysis		Multivariable regression analysis*	
Covariates	Odds ratio (95% Cl)	P- value	Odds ratio (95% Cl)	P- value
≥2 consecutive miscarriages compared to ≥2 non- consecutive miscarriages	1.4 (0.83-2.39)	0.21	0.90 (0.48-1.7)	0.75
≥3 consecutive miscarriages compared to ≥3 non- consecutive miscarriages	0.99 (0.6-1.6)	0.98	0.71 (0.39-1.3)	0.25

\* Corrected for known risk factors



### Conclusions

- Testing in recurrent miscarriage should take place if it results in effective treatments or the determination of prognosis.
- Number of miscarriages, maternal age and family history are established riskfactors for carrier status and pregnancy outcome
- No evidence is available to take into account the sequence of preceding miscarriages.



### **Advice**

- Refrain from fixed definitions in RM
- Use a broad definition: two preceding miscarriages
- After an accurate patient history, apply the available best evidence to determine whether to start testing in an individual patient or not
- Experimental diagnostics or treatment  $\rightarrow$  RCT



### Acknowledgment

**Center for Reproductive Medicine:** Mariëtte Goddijn Fulco van der Veen Maureen Franssen

**Department of Clinical Genetics:** Nico Leschot

**Department of Clinical Epidemiology:** Patrick Bossuyt Joke Korevaar

**Radboud University Medical Center, Nijmegen** Rosella Hermens Jan Kremer

Clinical Genetic Centers, The Netherlands: A.C. Knegt (AMC) K. Madan, A. Nieuwint (VUMC) R. Hochstenbach (UMC Utrecht) K.B.J. Gerssen-Schoorl, R.F.Suykerbuyk (UMC Groningen) C.H. Wouters (Erasmus MC) K.B.M. Hansson (LUMC)





